The Center for Drug Evaluation & Research’s comprehensive review of the advisory committee process offers an opportunity for industry to weigh in on possible improvements, starting with how external experts are vetted for membership as well as ideas to improve the clarity and utility of the questions that are asked at the end of the meeting.
CDER Director Patrizia Cavazzoni announced plans to improve the advisory committee process during the Biotechnology Innovation Organization’s recent annual meeting. The center, she said, wants to “get to a point...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?